Cornelis Kees
Directeur Général chez BIAL-Biotech Investments, Inc.
Profil
Cornelis Kees was the founder of Lysosomal Therapeutics, Inc. founded in 2011, where he held the title of President, Chief Executive Officer & Director.
Currently, he is the Chief Executive Officer at BIAL-Biotech Investments, Inc. and a Director at Rodin Therapeutics, Inc. He is also a Non-Executive Director at ReWind Therapeutics NV since 2020.
Previously, he was the President & Chief Executive Officer at FORUM Pharmaceuticals, Inc., Chief Executive Officer at Bionaut Pharmaceuticals, Inc., and Senior Vice President-Business Development at Biogen MA, Inc. He was also a Vice President at Gemini Consulting Group, Inc. from 1988 to 1995 and Vice President-Global Strategy at Monsanto Life Sciences Co. from 1996 to 1999.
Additionally, he served as a Member-Supervisory Board at Vivoryon Therapeutics NV.
Mr. Kees holds an MBA degree from INSEAD.
Postes actifs de Cornelis Kees
| Sociétés | Poste | Début |
|---|---|---|
Rodin Therapeutics, Inc.
 Rodin Therapeutics, Inc. BiotechnologyHealth Technology Rodin Therapeutics, Inc. develops first in class therapeutics for cognitive disorders. The company was founded by Bruce Booth in 2013 and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | - |
ReWind Therapeutics NV
 ReWind Therapeutics NV Pharmaceuticals: MajorHealth Technology ReWind Therapeutics NV is a biotech company based in Leuven, Belgium that develops first-in-class remyelinating therapies for myelin-related diseases. The Belgian company's aim is to bring these therapies into fast-track clinical development. Myelin-related diseases, such as multiple sclerosis, are those where the myelin sheath surrounding nerves is damaged, leading to deficient nerve transmission that may affect multiple functions, including sensation, cognition, and movement, among others. ReWind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis, or nerve injuries. The company's team has extensive R&D expertise and has built a strong patent estate for developing novel remyelination therapeutics. The company was founded in 2017 by Ku Leuven's Centre for Drug Design and Discovery (CD3) and Axxam S.p.A. The CEO of the company since 2021 is Anja Harmeier. | Directeur/Membre du Conseil | 02/09/2020 |
| BIAL-Biotech Investments, Inc. | Directeur Général | - |
Anciens postes connus de Cornelis Kees
| Sociétés | Poste | Fin |
|---|---|---|
| Monsanto Life Sciences Co. | Corporate Officer/Principal | 01/04/1999 |
Gemini Consulting Group, Inc.
 Gemini Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services Gemini Consulting Group, Inc. provides management consulting services. Its services range from management consulting, to the development of day surgery centers and hospitals. The company was founded by James B. McCarthy and is headquartered in Oak Brook, IL. | Corporate Officer/Principal | - |
| VIVORYON THERAPEUTICS N.V. | Directeur/Membre du Conseil | - |
Lysosomal Therapeutics, Inc.
 Lysosomal Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lysosomal Therapeutics, Inc. engages in the innovation, research, and development in the field of neurodegeneration. It focuses in lysosomal biology in developing novel small molecules for use in the treatment of neurodegenerative diseases. The company was founded by Dimitri Krainc, Joseph Mazzulli, Henri A. Termeer, Robert J. Carpenter, Peter Wirth, Edmund J. Sybertz, and Kees Cornelis Been in 2011 and is headquartered in Cambridge, MA. | Fondateur | - |
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Formation de Cornelis Kees
| INSEAD | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| VIVORYON THERAPEUTICS N.V. | Health Technology |
| Entreprise privées | 9 |
|---|---|
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
Gemini Consulting Group, Inc.
Gemini Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services Gemini Consulting Group, Inc. provides management consulting services. Its services range from management consulting, to the development of day surgery centers and hospitals. The company was founded by James B. McCarthy and is headquartered in Oak Brook, IL. | Commercial Services |
FORUM Pharmaceuticals, Inc.
 FORUM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology FORUM Pharmaceuticals, Inc. was engaged in the development of therapeutics for disorders of the central nervous system (CNS). It focused on discovering and developing treatments for important neurodegenerative diseases that explore novel mechanisms of action to potentially alter the progression of brain disease and provided improvement in cognitive and overall function. The company was founded by Thorsten Melcher in 2001 and was headquartered in Waltham, MA. | Health Technology |
Bionaut Pharmaceuticals, Inc.
 Bionaut Pharmaceuticals, Inc. BiotechnologyHealth Technology Bionaut Pharmaceuticals, Inc. develops and manufactures pharmaceuticals. It is a Biotechnology company using its technology to discover and advance novel small molecule drug candidates that affect well-validated disease pathways. Bionaut's business strategy is to license its candidates at a late preclinical stage to pharmaceutical and large biotech companies for development. The company was founded in August, 2000 by Mehran M. Khodadoust & Thomas Klein and is headquartered at Cambridge, MA. | Health Technology |
| Monsanto Life Sciences Co. | |
Rodin Therapeutics, Inc.
Rodin Therapeutics, Inc. BiotechnologyHealth Technology Rodin Therapeutics, Inc. develops first in class therapeutics for cognitive disorders. The company was founded by Bruce Booth in 2013 and is headquartered in Cambridge, MA. | Health Technology |
Lysosomal Therapeutics, Inc.
Lysosomal Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lysosomal Therapeutics, Inc. engages in the innovation, research, and development in the field of neurodegeneration. It focuses in lysosomal biology in developing novel small molecules for use in the treatment of neurodegenerative diseases. The company was founded by Dimitri Krainc, Joseph Mazzulli, Henri A. Termeer, Robert J. Carpenter, Peter Wirth, Edmund J. Sybertz, and Kees Cornelis Been in 2011 and is headquartered in Cambridge, MA. | Health Technology |
ReWind Therapeutics NV
ReWind Therapeutics NV Pharmaceuticals: MajorHealth Technology ReWind Therapeutics NV is a biotech company based in Leuven, Belgium that develops first-in-class remyelinating therapies for myelin-related diseases. The Belgian company's aim is to bring these therapies into fast-track clinical development. Myelin-related diseases, such as multiple sclerosis, are those where the myelin sheath surrounding nerves is damaged, leading to deficient nerve transmission that may affect multiple functions, including sensation, cognition, and movement, among others. ReWind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis, or nerve injuries. The company's team has extensive R&D expertise and has built a strong patent estate for developing novel remyelination therapeutics. The company was founded in 2017 by Ku Leuven's Centre for Drug Design and Discovery (CD3) and Axxam S.p.A. The CEO of the company since 2021 is Anja Harmeier. | Health Technology |
| BIAL-Biotech Investments, Inc. |